EULAR 2025 Symposium Highlights

0 SAR
Checkout

Overview

At EULAR 2025, our speakers explored the clinical relevance of CRP in rheumatic diseases. The session highlighted that both elevated and normal CRP levels can be seen in active disease and may impact treatment response. The discussion reinforced the need for a more personalised approach to guide therapy and improve patient outcomes

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Explore the clinical relevance of CRP in rheumatic diseases and understand how this parameter can guide treatment decision to improve patient outcomes

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-IX-SA-1188

Related Classes